The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis

Journal of Gastroenterology

Volumn 48, Issue 7, 2013, Pages 839-846

  Campanati, A ^a   Ganzetti, G ^a   Sario, A Di ^a   Damiani, A ^a   Sandroni, L ^a   Rosa, L ^a   Benedetti, A ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Etanercept; Non alcoholic fatty liver disease; Psoriasis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; ETANERCEPT; GLUCOSE; INSULIN; LIPID; METHOXSALEN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PUVA; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; WAIST HIP RATIO;

ADULT; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSORIASIS; PUVA THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84880798525     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0678-9     Document Type: Article

References (30)

1. Griffith CE, Barker JN. Pathogenesis and clinical feature of psoriasis. Lancet. 2007;370:263-71.
2. Leon AA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. JAMC. 2005;172(7):899-905.
3. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7(5):251-64.
4. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non alcoholic fatty liver disease in patients with chronic plaque type psoriasis. J Hepatol. 2009;51:758-64.
5. Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778-86.
6. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
7. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrel GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
8. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320-30.
9. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731-6.
10. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther. 2009;22(1):61-73.
11. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Patients. Adopted by the 18th WMA General Assembly 1964 and amended by the 29th, 35th, 41st and 48th WMA General Assemblies. John R Williams, University of Ottawa, Canada.
12. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563-9.
13. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156(5):945-50.
14. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel-III). JAMA. 2001;285:2486-97.
15. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis. 2010;42(4):272-82.
16. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and the visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708-15.
17. Garzotto N, Baratta S, Pistoso S, Faccincani C. Validation of a screening questionnaire for alcoholism (MAST) in an Italian sample. Compr Psych. 1988;29(3):323-9.
18. Duarte GV, Oliveira MD, Cardoso TM, Follador I, Silva TS, Cavalheiro CM, Nonato W, Carvalho EM. Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol. 2012. doi: 10.1111/j.1365-4632.2011.05270.x.
19. Gill T, Chittleborough C, Taylor A, Ruffin R, Wilson D, Philips P. Body Mass Index, waist hip ratio, and waist circumference: which measure to classify obesity? Soz Praventiv Med. 2003;48(3):191-200.
20. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-4.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-9.
22. Katz A, Nambi SS, Mather K, Baron AD, Follman DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402.
23. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10):721-8.
24. Pulzi FB, Cisternas R, Melo MR, Ribeiro CM, Malheiros CA, Salles JE. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol Metab Syndr. 2011;23;3(1):3.
25. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23(2):201-29.
26. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738-44.
27. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic liver disease. Q J Med. 2010;103:71-83.
28. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-808.
29. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102(12):2716-7.
30. Bosserhoff A, Hellerbrand C. Obesity and Fatty liver are 'grease' for the machinery of hepatic fibrosis. Dig Dis. 2011;29(4):377-83.